Innovative

Innovative

We focus on the performance and growth of promising technologies in the life science sector

Xlife Sciences AG

Who we are

Xlife Sciences AG is a listed (m:access: XLS) Swiss company focusing on the performance and growth of promising technologies and therapies in the life sciences sector. With a track record of more than 28 years, we bridge the gap between research and development and healthcare markets. Together with universities or industrial partners we lead projects through the proof of concept phase after a successful invention disclosure. Throughout the last 28 years, the team has led 14 of 18 project companies successfully to an exit. We actively advise new innovations from the spin-off to the later out-licensing, trade sale or even, possibly an IPO. Long-term strategic partnerships, built on trust and transparency, form the basis of our success.

Strategy

From out-licensing to licensing deal

about us

Our vision

Xlife Sciences AG focuses on the early stage of the life sciences industry. A company in the biotech sector goes through the following phases: invention disclosure, preclinical phase (followed by phase 1, phase 2 and phase 3) and finally, the approval. Xlife Sciences AG invests intelligently in the first two phases: invention disclosure and the preclinical phase, and thus has a comparatively above average success rate for the biotech sector.

Xlife

Our value chain

Xlife

Success factors in the biotech sector

our Team

Management, Senior Advisors and Business Development

Dr. Bernhard Scholz
Dr. Bernhard Scholz
President of the Board of Directors
Christian Faber
Christian Faber
Member of the Board of Directors
Mark S. Müller
Mark S. Müller
Member of the Board of Directors
Simon Schöni
Simon Schöni
Delegate of the Board of Directors
Georg Habighorst
Georg Habighorst
Senior Advisor
Matthias Bohn
Matthias Bohn
Senior Advisor
Marta Cao
Marta Cao
Senior Advisor
David L. Deck
David L. Deck
Senior Advisor
Matthias Weissl
Matthias Weissl
Head of Investor Relations
Elena Sachs
Elena Sachs
Marketing & Investor Relations
Kyra de Miroschedji
Kyra de Miroschedji
Scientific Lead of Lysatpharma GmbH
Jenny Nisser
Jenny Nisser
Research Assistant
Dr. Martin Steiner
Dr. Martin Steiner
CEO of Synimmune GmbH
Dr. Christoph Antz
Dr. Christoph Antz
CEO of Velabs Therapeutics GmbH
Dr. Gerhard Keilhauer
Dr. Gerhard Keilhauer
CEO of Araxa Biosciences GmbH
Matthias Steffen
Matthias Steffen
Managing Director of FUSE-AI GmbH

Advisory Board

Prof. Dr. habil. Michael B. Klein
Prof. Dr. habil. Michael B. Klein
President of the Advisory Board
Prof. Dr. Johannes Schumacher
Prof. Dr. Johannes Schumacher
Expert Human Genetics
Dr. med. Ralf Oettmeier
Dr. med. Ralf Oettmeier
Chief Physician Alpstein Clinic
Dr. med. Uwe Rudolf Max Reuter, DM
Dr. med. Uwe Rudolf Max Reuter, DM
Chief Physician CLINIC in LIFE
Rainer Schnetzer
Rainer Schnetzer
Industry Expert
Dr. rer. nat. Ludger Grosse-Hovest
Dr. rer. nat. Ludger Grosse-Hovest
Expert Immunology and Antibodies
Dr. Christoph Brücher
Dr. Christoph Brücher
Industry Expert

Sign up for our newsletter

We regularly report on the business development of Xlife Sciences AG and our project companies.